Journal of cancer research & therapy最新文献

{"title":"Synergistic antineoplastic action of 5-aza-2'deoxycytidine (decitabine) in combination with different inhibitors of enhancer of zeste homolog 2 (EZH2) on human lung carcinoma cells","authors":"Nascimento Asf, S. Côté, Jeong Ls, J. Yu, Momparler Rl","doi":"10.14312/2052-4994.2016-8","DOIUrl":"https://doi.org/10.14312/2052-4994.2016-8","url":null,"abstract":"Patients with metastatic lung cancer have a very poor prognosis indicating an urgent need to develop more effective chemotherapy. Aberrant promoter DNA methylation can result in the epigenetic silencing of tumor suppressor genes (TSGs) in lung cancer. 5-Aza2’deoxycytidine (5-Aza-CdR, decitabine), an inhibitor of DNA methylation, is able to reactivate silent TSGs. Trimethylation of histone H3 on lysine 27 (H3K27me3) by enhancer of zeste homolog 2 (EZH2) histone methyltransferase can also silence TSGs in lung cancer. 3-Deazaneplanocin-A (DZNep), an inhibitor of EZH2, up-regulates the expression of genes silenced by H3K27me3. In this study we compared the in vitro antineoplastic activity of different inhibitors of EZH2; DZNep, U-4149 and Gsk-126, alone and in combination with 5-Aza-CdR, on the human A549 lung adenocarcinoma cells. U-4149, an analogue of DZNep, was more potent than either DZNep or Gsk126. The reduction in colony formation was doseand time-dependent for each EZH2 inhibitors. Combination treatment of 5-Aza-CdR with the EZH2 inhibitors showed a synergistic antineoplastic activity. 5-Aza-CdR and U-4149 was the most potent combination. The in vitro antineoplastic activity of these agents was evaluated by inhibition of growth, colony formation, induction of senescence and apoptosis. All the drug combinations induced signs of senescence and apoptosis. Analysis by gene expression by qRT-PCR showed that the combinations increased the expression of several TSGs to a greater extent that either agent alone. In conclusion, epigenetic therapy that specifically targets DNA and histone methylation has interesting potential for the treatment of lung cancer and merits further investigation.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"64 1","pages":"42-49"},"PeriodicalIF":0.0,"publicationDate":"2016-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74594086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid tumor progression in a patient with HPV type 16 associated anal squamous cell carcinoma suffering from long-standing Crohn's disease: A case report","authors":"A. Fischer, T. Krause, H. Steinbrück, H. Schildhaus, C. Hoppenau, R. Hesterberg, J. Rüschoff","doi":"10.14312/2052-4994.2016-9","DOIUrl":"https://doi.org/10.14312/2052-4994.2016-9","url":null,"abstract":"Background and aim: Squamous cell carcinoma (SCC) is the most common cancer of the anal region, typically associated with high-risk (hr) HPV infection. Furthermore, there is evidence that Crohn's disease predisposes to adenocarcinoma in patients with perianal disease. Materials and methods: A 57-year old patient presenting with long history of Crohn's disease since the age of mid-twenties, went through several surgeries including ileocolectomy and anal fistula resection, combined with immunosuppressive therapy additionally periodically since 2008. One year before death (in 2015) a painful fistula was diagnosed with extensive high grade anal intraepithelial neoplasia (AINHG) and evidence of invasive growth as non-keratinizing SCC. Tissue samples from several previous and current resection specimens were re-evaluated and extensively investigated for Crohn ́s type inflammation, dysplasia and HPV both by immunohistochemistry (p16/Ki67) and molecular subtyping of HPV. Results: AIN-HG and invasive anal squamous cell carcinoma turned out to be strongly positive for p16/ Ki67 staining and molecular analysis disclosed a HPV-16 subtype. In contrast, HPV-analysis was negative in all available previous tissue samples including one anal fistula resected five years before (in 2009) which was lined by non-keratinized squamous epithelium without any evidence of dysplasia. Thus, the patient was diagnosed as Crohn's disease with hr-HPV infection that rapidly ( 5ys) progressed to AIN-HG and anal SCC. Finally, osseous metastases occurred and the patient died shortly after. Conclusions: This case of a patient diagnosed with SCC of the anal canal in combination with Crohn's disease as well as HPV Type 16 infection, points to the pathomechanism leading to dysplasia and finally cancer. We assume that immunosuppressive therapy in Crohn's disease may predispose to both persistent HPV infection and HPV related invasive anal carcinoma. The accelerated progression of HPV associated neoplasia in immunosuppressed patients might represent a fast-tracked process of the long-term course of precancerous or cancerous lesions in immunocompetent hosts. This might implicate, that there is a need to re-evaluate current screening guidelines for anal cancer in patients with chronic inflammatory bowel disease under immunosuppressive therapy.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"3 1","pages":"50-54"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78041804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Newly isolated compounds from West African Sorghum bicolor leaf sheaths Jobelyn® show potential in cancer immunosurveillance","authors":"Makanjuola Sbl, D. Dosunmu, L. Ajonuma, A. Ogundaini, O. Okubena","doi":"10.14312/2052-4994.2016-6","DOIUrl":"https://doi.org/10.14312/2052-4994.2016-6","url":null,"abstract":"Jobelyn, a West African pharmaceutical product derived from Sorghum bicolor leaf sheaths has been shown to possess strong antitumour and anti-inflammatory properties. This study aims to evaluate the expression of cell surface markers CD69 on activated natural killer (NK) cells; natural killer T (NKT) cells; and T cells from human peripheral blood mononuclear cells (PBMC) upon treatment with Jobelyn fractions using flow cytometry. Blood was collected from 3 donors, PBMC were isolated and plated with each specific fraction: crude extracts (J); ethyl acetate (JE); n-butanol (JB); secondary compounds from JE (JE5; JE6); purified and semi-purified compounds from JE5 (P8 and P9) at specific concentrations (2.5-500 g/ml). For the crude extracts, JE was the most active showing significant expression of CD69 on NK-(P  0.001), T(P  0.0001), and NKTtreated cells (P  0.0001). Secondary compound, JE5, of JE also showed significant CD69 expression on NK(P  0.018) and T-treated cells (P  0.027), but not on NKT-treated cells (P  0.084). Similarly, the semi-purified compound P8, from JE5 showed increased expression of CD69 on NK(P0.023); T(P  0.001), and NKT-treated cells (P0.007). Evidence of innate effector cells activation by ethanolic extracts of Jobelyn suggests that this variety of Sorghum may be able to mediate direct cell cytotoxicity supporting the control and clearance of a number of tumour cells.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"10 1","pages":"31-37"},"PeriodicalIF":0.0,"publicationDate":"2016-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75471288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calcification of peritoneum and peritoneal fluid perfusion malfunction in carcinomatosis of serous membranes of peritoneal cavity","authors":"Gantsev Sk, K. Umezava, Vagapova Vs, Gantsev Ks, Solomenny Sv, Kzyrgalin, Yamidanov Rs, Gantseva Ea","doi":"10.14312/2052-4994.2016-7","DOIUrl":"https://doi.org/10.14312/2052-4994.2016-7","url":null,"abstract":"The article describes the peritoneal calcification in peritoneal carcinomatosis, as well as its possible role in the development of carcinomatosis within the frames of the authors’ alternative theory. The analysis of the \"serous-lymph hatches\" condition of the intact peritoneum and peritoneum in carcinomatosis was carried out. Also the elemental quantitative calcium determination in the intact peritoneum and the peritoneum in peritoneal carcinomatosis was carried out using the atomic emission spectrometry.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"1 1","pages":"38-41"},"PeriodicalIF":0.0,"publicationDate":"2016-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90377228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EYA1 expression and subcellular localization in neuroblastoma and its association with prognostic markers.","authors":"Jeanne N Hansen,&nbsp;Louis T Lotta,&nbsp;Allison Eberhardt,&nbsp;Nina F Schor,&nbsp;Xingguo Li","doi":"10.14312/2052-4994.2016-3","DOIUrl":"https://doi.org/10.14312/2052-4994.2016-3","url":null,"abstract":"<p><p>Neuroblastoma, the most frequently occurring extracranial solid tumor of childhood, arises from neural crest-derived cells that are arrested at an early stage of differentiation in the developing sympathetic nervous system. There is an urgent need to identify clinically relevant biomarkers for better prognosis and treatment of this aggressive malignancy. Eyes Absent 1 (EYA1) is an essential transcriptional coactivator for neuronal developmental programs during organogenesis. Whether or not EYA1 is implicated in neuroblastoma and subcellular localization of EYA1 is relevant to clinical behaviour of neuroblastoma is not known. We studied EYA1 expression and subcellular localization by immunohistochemistry in tissue microarrays containing tumor specimens from 98 patients, 66 of which were characterized by known clinical prognostic markers of neuroblastoma. Immunostaining results were evaluated and statistically correlated with the degree of histologic differentiation and with neuroblastoma risk stratification group characteristics, including stage of disease, patient age, tumor histology and mitosis-karyorrhexis index (MKI), respectively. We found that EYA1 levels were significantly higher in neuroblastomas than in ganglioneuromas and ganglioneuroblastomas. EYA1 was more highly expressed in stage 1,2,3 or 4S tumors as compared to stage 4 tumors (P<0.01). Tumors with high levels of nuclear EYA1 were more frequently associated with high nuclear MYCN levels. These results suggest that modulation of expression and intracellular localization of EYA1 in neural crest cells may provide a novel direction for therapeutic strategies.</p>","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"4 2","pages":"11-18"},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35174799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and pathological response to pre-operative crizotinib in a patient with ALK-translocated NSCLC","authors":"Catania C, Barberis M, Petrella F, Solli P, DePas Tm, Perrone G, Gianluca S, Noberasco C, Passaro A, Rocco Eg, deMarinis F","doi":"10.14312/2052-4994.2016-10","DOIUrl":"https://doi.org/10.14312/2052-4994.2016-10","url":null,"abstract":"A 65-year-old non-smoker female was diagnosed with lung adenocarcinoma clinically staged as IV M1a because of bilateral pulmonary lesions. After a differential response to chemotherapy, further analyses allowed us to re-stage the tumor as a synchronous bilateral local disease with unilateral ALK (Anaplastic lymphoma kinase) rearrangement. Combined treatment with chemotherapy, crizotinib and surgery, with clinical and pathological tumor-response to pre-operative crizotinib, obtained complete tumors remission, and the patient is still disease free after 11 months since the last tumor resection. As far as we know this is the first report of a clinical and pathological regression of an early-stage ALK-rearranged NSCLC treated with neo-adjuvant crizotinib. This report supports further studies to assess activity and efficacy of ALK–inhibitors in neoadjuvant setting.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"76 1","pages":"55-58"},"PeriodicalIF":0.0,"publicationDate":"2016-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90681430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>KRAS</i> testing and first-line treatment among patients diagnosed with metastatic colorectal cancer using population data from ten National Program of Cancer Registries in the United States.","authors":"Adriana Rico, Lori A Pollack, Trevor D Thompson, Mei-Chin Hsieh, Xiao-Cheng Wu, Jordan J Karlitz, Dee W West, John M Rainey, Vivien W Chen","doi":"10.14312/2052-4994.2017-2","DOIUrl":"10.14312/2052-4994.2017-2","url":null,"abstract":"<p><strong>Background: </strong>In 2011, the National Comprehensive Cancer Network (NCCN) recommended <i>KRAS</i> testing for metastatic colorectal cancer (mCRC) patients. Our study assessed <i>KRAS</i> testing prevalence and its association with socio-demographic and clinical factors and examined first-line treatment.</p><p><strong>Methods: </strong>Ten state population-based registries supported by Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries (NPCR) collected detailed cancer information on mCRC cases diagnosed in 2011, including <i>KRAS</i> biomarker testing and first-line treatment from ten central cancer registries. Data were analyzed with Chi-square tests and multivariate logistic regression.</p><p><strong>Results: </strong>Of the 3,608 mCRC cases, 27% (n = 992) had a documented <i>KRAS</i> test. Increased age at diagnosis (p < 0.0001), racial/ethnic minorities (p = 0.0155), public insurance (p = 0.0018), and lower census tract education (p = 0.0023) were associated with less <i>KRAS</i> testing. Significant geographic variation in <i>KRAS</i> testing (p < 0.0001) ranged from 46% in New Hampshire to 18% in California. After adjusting for all covariates, age and residence at diagnosis (both p < 0.0001) remained predictors of <i>KRAS</i> testing. Non-Hispanic Blacks had less <i>KRAS</i> testing than non-Hispanic Whites (OR = 0.77, 95% CI = 0.61-0.97). Among those tested and found to have normal (wild-type) <i>KRAS</i>, 7% received anti-EGFR treatment; none received such treatment among those with <i>KRAS</i> mutated gene.</p><p><strong>Conclusions: </strong>Despite NCCN guideline recommendations, 73% of mCRC cases diagnosed in 2011 had no documented <i>KRAS</i> test. Disparities in <i>KRAS</i> testing existed based on age, race, and residence at diagnosis.</p><p><strong>Impact: </strong>These findings show the capacity of monitoring <i>KRAS</i> testing in the US using cancer registry data and suggest the need to understand the low uptake of <i>KRAS</i> testing, and associated treatment choices during the first year since diagnosis.</p>","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"5 2","pages":"7-13"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472357/pdf/nihms856719.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35099632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How health system factors influence referral decisions in patients that may have cancer: European symposium report","authors":"Michael Harris, P. Frey, M. Esteva, Svjetlana Gašparović-Babić, M. Marzo-Castillejo, Davorina Petek, M. Šter, H. Thulesius","doi":"10.14312/2052-4994.2016-2","DOIUrl":"https://doi.org/10.14312/2052-4994.2016-2","url":null,"abstract":"Abstract Objective: To identify the system and other non-clinical factors that may influence a General Practitioners’ decision on whether to refer a patient who may have cancer. Study design: Expert group discussion and consensus formation. Methods: A group of eight General Practitioner (GP) researchers from Croatia, England, Slovenia, Spain, Sweden and Switzerland used brainstorming to identify the non-clinical factors that could affect GPs’ decision-making when faced with patients that might have cancer. The group refined and came to a consensus on these factors. Results: Many non-clinical factors are likely to have a significant impact on referral decisions. These include levels of gatekeeping responsibility, funding systems, access to special investigations, fear of litigation, and relationships with specialist colleagues. Conclusions: Many patients with cancer present without red-flag symptoms, but nevertheless still cause a feeling of concern in their GPs. How a health system is organised is likely to influence on how GPs act on those concerns.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"66 1","pages":"7-10"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83937215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic obstructive pulmonary disease with lung cancer: Prevalence, severity, and common pathogenesis","authors":"John P. Griffin, E. A. Tolley, M. K. Zaman, H. Niell, F. Hammond Cole, D. Weiman","doi":"10.14312/2052-4994.2016-1","DOIUrl":"https://doi.org/10.14312/2052-4994.2016-1","url":null,"abstract":"Objectives: To develop a clinical prediction model of contribution of chronic obstructive pulmonary disease (COPD) to the pathogenesis of lung cancer, by reporting the estimated prevalence and severity by GOLD criteria in a single-institution cohort of patients with newly diagnosed lung cancer. Primary objective was investigating the effects of impaired lung function with various histological cell types on crude survival, while considering the initial staging of disease extent. Materials & methods: A total of 441 patients, in this historical cohort from electronic medical records, completed spirometry prior to invasive diagnostic procedures and initial treatment of their lung cancer. All statistical analyses, including ANOVA and survival analysis, were performed using SAS version 9.1 software. Results: Estimated prevalence of COPD was 79.1% (95% confidence interval: 71.3%-82.9%). Lung function as measured by spirometry was a significant predictor of survival time in months (p.0001) both with and without adjusting for tumor-cell-type, age, and stage of disease. Median survival was similar (p0.32) and longer among those patients with normal pulmonary function, those with restrictive disease patterns, and those with COPD–GOLD-1 defects. Median survival was shortest among patients with COPD–GOLD-4 impairment (p0.001). Those patients with COPD–GOLD-2 and COPD-GOLD-3 impairment levels had intermediate survival times (p0.003). Conclusions: This investigation suggests that strategies for early detection and slowing the progression of COPD before the development of lung cancer might increase patient survival. As demonstrated in this study, the presence and severity of COPD in lung cancer patients is an independent predictor of survival time, different from the established staging of initial extent of disease.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"158 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77900822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advance care planning in patients with brain tumours: A prospective cohort study","authors":"K. Song, B. Amatya, F. Khan","doi":"10.14312/2052-4994.2015-12","DOIUrl":"https://doi.org/10.14312/2052-4994.2015-12","url":null,"abstract":"Objectives: To assess and understand the awareness and experience of brain tumour (BT) patients in discussing Advance Care Planning (ACP), to identify main symptoms experienced, physical and functional status perceived quality of life, and level of coping. Methods: A prospective cohort study with an initial open-ended questionnaire followed by semi-structured interview questions regarding ACP with 18 patients diagnosed with BT (WHO Grade I-IV, metastatic BT) in hospital and community. Standardized assessments measured coping strategies, and quality of life (QoL). Interview transcripts regarding ACP discussions were analyzed, coded and interpreted using qualitative analytic techniques for thematic analyses. Results: Participants' mean age was 51 years (range 22-65 years), female (61%); median time since BT diagnosis was 1.5 years and just over half (56%) had glioblastoma multiforme (GBM). Fatigue was the most common symptom reported by 83% of participants. Overall, participants indicated good QoL and used more problem-focused coping strategies including ‘acceptance’ and ‘positive reframing’. Thematic analyses indicated that participants had limited awareness and understanding of ACP, variable views on appropriate timing of ACP discussions and change of decisions over illness trajectory. Most felt able to discuss ACP and preferred dedicated sessions by a trained health professional. Conclusion: This study highlights the importance of providing timely information regarding ACP to BT patients during the course of their disease. Established ACP discussions have an important role in enhancing patient autonomy and to guide delivery of end-of-life care. The demonstrated low uptake of ACP in this pilot study shows need for improved awareness in clinical practice for timely ACP discussions and multifaceted interventions system-wide in implementing ACP.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"58 1","pages":"85-91"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80521400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}